Compounded Semaglutide for Weight Loss in Noblesville, IN

Compounded semaglutide for weight loss is a patient-specific prescription option that may be considered only when applicable federal and state compounding requirements are satisfied.

Semaglutide belongs to a class of medications called glucagon-like peptide-1 receptor agonists, commonly called GLP-1 receptor agonists. FDA-approved semaglutide has extensive clinical evidence supporting weight reduction in adults with obesity and in adults with overweight who have at least one weight-related medical condition.

However, an important distinction must be made between FDA-approved semaglutide and compounded semaglutide.

Compounded semaglutide:

• Is not FDA-approved
• Is not an FDA-approved generic version of Wegovy, Ozempic or another semaglutide product
• Does not undergo FDA premarket review for safety, effectiveness or quality
• May differ in concentration, container, formulation and administration instructions
• Should not be assumed to produce the exact clinical results reported for FDA-approved semaglutide products

The national shortage of semaglutide injection products was declared resolved by FDA in February 2025. As a result, the shortage-related flexibility that previously allowed broader production of compounded semaglutide has ended.

Under current federal policy, patient-specific compounding may still be appropriate in limited circumstances when all applicable requirements are met, including situations in which a prescriber determines and documents that a compounded preparation provides a clinically significant difference for an identified individual patient.

A physician-guided medical weight-loss consultation can help determine whether an FDA-approved semaglutide product, another FDA-approved weight-management medication or a legally appropriate compounded preparation may fit your individual medical needs.

To discuss weight-management options in Noblesville, IN, call (765) 259-0545 or contact Charles Turner MD online.

What Is Semaglutide?

Semaglutide is a long-acting GLP-1 receptor agonist designed to activate the human glucagon-like peptide-1 receptor.

GLP-1 is a naturally occurring hormone released from the gastrointestinal tract after eating.

GLP-1 signaling contributes to:

• Appetite regulation
• Satiety
• Insulin secretion when glucose is elevated
• Glucagon regulation
• Gastric emptying
• Blood-glucose control

Semaglutide was engineered to resist rapid enzymatic breakdown and remain active much longer than naturally occurring GLP-1.

This allows approved injectable semaglutide products to be administered once weekly.

How Does Semaglutide Help With Weight Loss?

Semaglutide primarily supports weight reduction by influencing appetite and food intake.

GLP-1 receptors are present in brain regions involved in hunger, reward and energy intake.

Clinical research has found that semaglutide can help patients:

• Feel full sooner
• Remain satisfied longer after meals
• Reduce hunger
• Improve control over eating
• Reduce selected food cravings
• Consume fewer calories

Weight reduction occurs gradually and varies significantly among patients.

Semaglutide does not directly melt fat or replace the need for adequate nutrition, physical activity, sleep and long-term weight-management planning.

What Is Compounded Semaglutide?

Compounding is the preparation of an individualized medication by a qualified pharmacy or physician under applicable federal and state law.

A compounded medication may differ from a commercially manufactured FDA-approved product in ways such as:

• Strength
• Dosage form
• Inactive ingredients
• Concentration
• Container or delivery system

Compounding can serve an important medical purpose when an individual patient's needs cannot be met by an available FDA-approved drug.

It is not intended to function as a routine manufacturing pathway for mass-market copies of commercially available medications.

Is Compounded Semaglutide FDA-Approved?

No.

FDA does not approve compounded semaglutide products before they are dispensed.

This means FDA does not conduct the same premarket evaluation of each compounded product for:

• Safety
• Effectiveness
• Manufacturing consistency
• Potency
• Stability
• Quality
• Labeling

This distinction should be clearly explained before treatment.

Is Compounded Semaglutide a Generic Version of Wegovy?

No.

A generic drug is an FDA-approved medication that has undergone regulatory review demonstrating that it meets applicable requirements for equivalence to the reference product.

Compounded semaglutide is not an FDA-approved generic.

FDA has specifically warned healthcare and telehealth marketers not to describe compounded GLP-1 medications as:

• Generic versions of FDA-approved drugs
• The same as FDA-approved medications
• FDA-approved compounded drugs
• Clinically proven to produce the same results as FDA-approved products

A compounded product should be identified accurately as a compounded prescription.

Why Did Compounded Semaglutide Become So Common?

Semaglutide injection products entered shortage beginning in 2022 as demand for GLP-1 medications increased rapidly.

When an FDA-approved medication appears on FDA's drug shortage list, certain restrictions on compounding essentially copies of the approved medication may be temporarily different.

This shortage environment contributed to rapid growth in compounded semaglutide prescribing and telehealth weight-loss programs.

FDA determined on February 21, 2025 that the national semaglutide injection shortage had been resolved.

The transitional enforcement-discretion periods subsequently ended.

Compounding rules that restrict routine copies of commercially available semaglutide therefore apply again.

Can Semaglutide Still Be Compounded in 2026?

Potentially, but the circumstances are substantially narrower than during the national shortage.

Under Section 503A of the Federal Food, Drug, and Cosmetic Act, qualifying patient-specific compounding requires compliance with multiple conditions.

Among other requirements:

• The medication generally must be compounded for an identified individual patient based on a valid prescription
• The compounder cannot regularly or in inordinate amounts make a product that is essentially a copy of a commercially available drug
• A prescriber may determine that a change in the compounded product creates a significant difference for an identified individual patient
• The determination should be documented appropriately

FDA's current policy considers factors including the active ingredient, strength and route when determining whether a compounded preparation is essentially a copy.

The fact that a patient prefers a compounded product or that it costs less does not by itself establish a clinically significant difference.

What Does a Clinically Significant Difference Mean?

Federal compounding policy allows an important patient-specific exception when a prescriber determines that a change in a compounded drug produces a significant difference for an identified individual patient.

The determination is medical and patient-specific.

It should not be treated as a blanket justification for prescribing compounded semaglutide to every patient.

Depending on an individual situation, a clinician may need to consider factors such as:

• Medical intolerance to a particular formulation component
• A clinically necessary dosage form or strength
• Another documented patient-specific need that cannot appropriately be met with an available approved product

Whether a particular difference qualifies must be determined by the prescriber and compounder under current law and guidance.

Does Adding Vitamin B12 Make Compounded Semaglutide Automatically Legal?

No.

Some compounded semaglutide products include cyanocobalamin, or vitamin B12.

Simply adding B12 does not automatically mean a semaglutide formulation is no longer considered essentially a copy of a commercially available medication.

FDA's April 2026 guidance specifically explains that a compounded product containing semaglutide plus another active ingredient such as vitamin B12 may still be considered essentially a copy depending on the route, strengths and other circumstances.

A clinician should not represent B12 addition as a universal legal or clinical justification for compounding.

What About Semaglutide Sodium or Semaglutide Acetate?

FDA has specifically warned about compounded products made with semaglutide salt forms, including:

• Semaglutide sodium
• Semaglutide acetate

These are chemically different active ingredients from the semaglutide used in FDA-approved medications.

FDA states that it does not have information showing that these salt forms have the same chemical and pharmacological properties as the active ingredient used in approved semaglutide products and that it is not aware of a lawful basis for their use in compounding.

Patients considering a compounded product should ask exactly which form of semaglutide is being prescribed.

FDA-Approved Semaglutide for Weight Loss

Wegovy is the FDA-approved semaglutide product specifically indicated for chronic weight management.

As of 2026, FDA-approved Wegovy options include:

• Subcutaneous Wegovy injection
• Oral Wegovy tablets for adults

FDA-approved Wegovy is used together with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in appropriate patients.

Approved indications include adults with obesity and adults with overweight who have at least one weight-related comorbid condition.

Wegovy injection also has a pediatric weight-management indication for patients age 12 years and older with obesity.

What Is Wegovy HD?

The current FDA-approved Wegovy injection label includes a higher-dose 7.2 mg presentation, commonly referred to as Wegovy HD.

This is an FDA-approved commercial semaglutide formulation with its own prescribing information.

The existence of additional approved strengths is relevant when determining whether a compounded strength represents a clinically significant difference for an individual patient.

Patients should not attempt to convert doses between products without medical guidance.

What Is Oral Wegovy?

FDA-approved Wegovy tablets provide an oral semaglutide option for adults who meet the approved weight-management or cardiovascular-risk-reduction indications.

Oral Wegovy has a specific administration and dose-escalation schedule because semaglutide absorption from the gastrointestinal tract differs from subcutaneous injection.

A compounded oral semaglutide preparation should not be assumed to have the same absorption, bioavailability or clinical evidence as FDA-approved Wegovy tablets.

Compounded Semaglutide vs. Wegovy

Comparison	Compounded Semaglutide	Wegovy
FDA approval	No	Yes
Weight-management indication	No FDA-approved indication for the compounded preparation	FDA-approved for appropriate adults and selected adolescents
Premarket FDA review	No	Yes
Clinical-trial evidence	Individual compounded formulations generally have not undergone large weight-loss trials	Extensive randomized clinical-trial program
Strength and delivery	May vary by compounder	Standardized FDA-approved injection and tablet formulations
When considered	Only when applicable compounding requirements and patient-specific medical needs are satisfied	When a patient meets the approved indication and has no contraindication

Compounded Semaglutide vs. Ozempic

Ozempic also contains semaglutide, but its FDA-approved indications are related primarily to type 2 diabetes and associated cardiovascular or kidney risk in appropriate patients.

Ozempic is not the FDA-approved semaglutide brand specifically labeled for chronic weight management.

Using the term “compounded Ozempic” is therefore misleading.

A compounded semaglutide preparation is not Ozempic and should not be represented as an Ozempic generic.

Compounded Semaglutide vs. Rybelsus

Rybelsus is an FDA-approved oral semaglutide product used for type 2 diabetes.

Wegovy tablets are now a separate FDA-approved oral semaglutide formulation for adult weight reduction and cardiovascular-risk reduction.

These commercial tablets have specific formulation technology and administration instructions.

A compounded semaglutide capsule, troche or oral liquid should not be assumed equivalent to either FDA-approved oral product.

How Much Weight Can Patients Lose With Semaglutide?

The strongest weight-loss estimates come from trials of FDA-approved semaglutide formulations, not compounded products.

In the STEP 1 randomized trial, 1,961 adults with overweight or obesity without diabetes received semaglutide 2.4 mg or placebo plus lifestyle intervention for 68 weeks.

Average body-weight change was:

• 14.9% reduction with semaglutide
• 2.4% reduction with placebo

Among semaglutide-treated participants:

• 86.4% lost at least 5% of body weight
• 69.1% lost at least 10%
• 50.5% lost at least 15%

These results demonstrate the effectiveness of the studied FDA-approved semaglutide regimen.

They should not be advertised as guaranteed results from a compounded preparation.

Two-Year Semaglutide Weight-Loss Results

The STEP 5 trial followed adults with overweight or obesity for 104 weeks.

Mean body-weight change at two years was:

• 15.2% reduction with semaglutide
• 2.6% reduction with placebo

More than three-quarters of semaglutide-treated participants achieved at least 5% weight loss at week 104.

The study supports semaglutide as a long-term obesity treatment rather than a short-term crash-weight-loss medication.

Why Ongoing Treatment May Matter

Obesity is a chronic, relapsing medical condition.

The STEP 4 randomized withdrawal trial demonstrated that participants who continued semaglutide after an initial treatment period continued losing weight, while participants switched to placebo regained weight.

The STEP 1 extension also found substantial weight regain after semaglutide was discontinued.

One year after treatment withdrawal, participants regained approximately two-thirds of their prior semaglutide-associated weight loss on average.

This does not mean every patient must remain on medication indefinitely.

It does mean that maintenance planning should be discussed before starting treatment.

Semaglutide and Appetite Control

The STEP 5 program also evaluated eating behavior over two years.

Participants receiving semaglutide reported improvements involving:

• Craving control
• Ability to resist selected cravings
• Control of eating
• Hunger and fullness during parts of the study

This aligns with the medication's central appetite-regulating mechanism.

Long-term success is strengthened when medication is paired with an individualized nutrition strategy rather than relying on appetite suppression alone.

Semaglutide and Prediabetes

Weight loss can substantially influence glucose regulation.

A pooled analysis of the STEP 1, STEP 3 and STEP 4 programs evaluated 3,375 adults with overweight or obesity.

Among participants with prediabetes at baseline, substantially more patients receiving semaglutide achieved normoglycemia during treatment compared with placebo.

In STEP 1, for example, 84.1% of participants with baseline prediabetes who received semaglutide had normoglycemia at week 68.

Semaglutide should still be paired with appropriate evaluation of insulin resistance , glucose and hemoglobin A1c.

Semaglutide and Cardiovascular Risk

Semaglutide's clinical evidence extends beyond the number on the scale.

The SELECT trial enrolled 17,604 adults with overweight or obesity and established cardiovascular disease who did not have diabetes.

During approximately 40 months of follow-up, a major cardiovascular event occurred in:

• 6.5% of participants assigned to semaglutide
• 8.0% of participants assigned to placebo

This represented a 20% relative reduction in the primary composite outcome of cardiovascular death, nonfatal heart attack or nonfatal stroke.

FDA subsequently approved Wegovy to reduce major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight.

This approved cardiovascular claim applies to Wegovy, not automatically to compounded semaglutide.

Long-Term Weight Findings From SELECT

A prespecified analysis of the SELECT trial reported that weight reduction with semaglutide continued through approximately 65 weeks and remained sustained for up to four years.

At week 208, average weight change was:

• 10.2% reduction with semaglutide
• 1.5% reduction with placebo

The SELECT population differed from STEP 1 because participants had established cardiovascular disease and were older on average.

Results from different trial populations should not be treated as identical expectations for every patient.

Semaglutide and Knee Osteoarthritis

Weight reduction can reduce mechanical load on weight-bearing joints.

The STEP 9 randomized trial evaluated adults with obesity and moderate-to-severe knee osteoarthritis pain.

Once-weekly semaglutide produced significantly greater weight reduction and improvement in knee osteoarthritis pain than placebo.

Patients with obesity-related joint symptoms may also benefit from evaluation for osteoarthritis and knee pain.

Who May Be a Candidate for Medical Semaglutide Treatment?

FDA-approved Wegovy is indicated for chronic weight management in appropriate adults with obesity or overweight accompanied by at least one weight-related medical condition.

Weight-related conditions can include:

• High blood pressure
• Abnormal cholesterol
• Type 2 diabetes
• Obstructive sleep apnea
• Cardiovascular disease
• Other obesity-related health conditions

A physician should evaluate more than BMI alone.

Medical assessment may include:

• Weight history
• Previous weight-loss attempts
• Current medications
• Metabolic health
• Cardiovascular risk
• Eating patterns
• Sleep
• Hormonal or endocrine conditions
• Pregnancy plans
• Medication contraindications

When Would a Compounded Product Be Considered Instead?

Because FDA-approved semaglutide is commercially available, a compounded product should not be treated as the default version of semaglutide.

A patient-specific compounded preparation may be considered only when the prescriber and compounder determine that current legal requirements are met.

The clinical record should identify why the patient's needs cannot appropriately be met with an available FDA-approved product when such a determination is required.

Cost alone should not be presented as a medical reason that automatically authorizes compounding.

What Should a Physician Evaluate Before Prescribing Semaglutide?

A comprehensive weight-management evaluation may review:

• Current weight and BMI
• Waist circumference
• Body-fat and lean-mass measurements
• Blood pressure
• Glucose and hemoglobin A1c
• Lipid profile
• Kidney function
• Liver function
• History of pancreatitis
• Gallbladder disease
• Gastrointestinal symptoms
• Personal or family thyroid-cancer history
• Pregnancy plans
• Current medications

Patients may also benefit from body composition analysis and metabolic testing .

Body Composition Matters During Weight Loss

The goal of medical weight management is not simply to make the scale move downward.

Weight loss can include both fat mass and lean tissue.

Tracking body composition can help a clinician evaluate whether the treatment plan is supporting:

• Reduction in body fat
• Reduction in visceral fat
• Preservation of lean mass
• Maintenance of strength
• Long-term metabolic health

Body composition tracking can be especially useful during substantial weight loss.

Preserving Muscle During Semaglutide Treatment

Rapid or substantial weight reduction can include loss of lean mass.

A comprehensive program may include:

• Adequate dietary protein
• Resistance training
• Appropriate total calorie intake
• Correction of nutritional deficiencies
• Monitoring of strength and function

Patients at increased risk of muscle loss may require additional evaluation for sarcopenia.

Nutrition During Semaglutide Weight Loss

Semaglutide can substantially reduce appetite.

That can make it easier to reduce calorie intake, but it can also make it harder for some patients to consume adequate:

• Protein
• Fiber
• Fluids
• Vitamins
• Minerals

Nutritional counseling can help patients build a sustainable eating pattern rather than simply eating as little as possible.

Exercise During Semaglutide Treatment

Physical activity remains important even when medication produces substantial weight loss.

A balanced program may include:

• Resistance training
• Aerobic exercise
• Daily walking
• Mobility and flexibility work

Personal training for weight loss may help patients preserve muscle, improve fitness and support long-term maintenance.

Common Side Effects of Semaglutide

The current FDA-approved Wegovy prescribing information lists gastrointestinal symptoms among the most common adverse reactions.

Common effects can include:

• Nausea
• Diarrhea
• Vomiting
• Constipation
• Abdominal pain
• Indigestion
• Abdominal bloating
• Belching
• Flatulence
• Gastroesophageal reflux symptoms
• Headache
• Fatigue
• Dizziness
• Hair loss

Symptoms are often most noticeable during dose escalation.

Severe or persistent symptoms require medical review.

Important Semaglutide Safety Considerations

Semaglutide has clinically important warnings and precautions.

Potential concerns include:

• Acute pancreatitis
• Gallbladder disease
• Kidney injury associated with dehydration
• Severe gastrointestinal reactions
• Hypoglycemia when combined with insulin or selected diabetes medications
• Diabetic retinopathy complications in patients with type 2 diabetes
• Increased resting heart rate
• Serious hypersensitivity reactions
• Potential aspiration risk during anesthesia or deep sedation because GLP-1 medications can affect gastric emptying

Patients should tell clinicians performing surgery, anesthesia or endoscopic procedures that they use semaglutide or another GLP-1 medication.

Semaglutide and Pancreatitis

Acute pancreatitis has been observed in patients treated with GLP-1 receptor agonists.

Symptoms can include persistent severe abdominal pain that may radiate to the back, with or without vomiting.

Patients with symptoms concerning for pancreatitis require prompt medical evaluation.

Semaglutide and Gallbladder Disease

Gallstones and gallbladder inflammation can occur during substantial weight loss and have also been reported in semaglutide clinical trials.

Patients should report symptoms such as:

• Persistent right-upper-abdominal pain
• Pain after meals
• Fever
• Jaundice
• Vomiting

Gallbladder symptoms may require laboratory testing and imaging.

Semaglutide and Gastroparesis

GLP-1 receptor agonists can delay gastric emptying.

Current Wegovy labeling does not recommend the medication for patients with severe gastroparesis.

Patients with severe nausea, recurrent vomiting, persistent fullness or significant upper-abdominal symptoms should tell their physician before starting therapy.

Thyroid C-Cell Tumor Warning

Wegovy carries a boxed warning regarding thyroid C-cell tumors observed in rodents.

It is unknown whether semaglutide causes medullary thyroid carcinoma in humans.

FDA-approved Wegovy is contraindicated in patients with:

• A personal history of medullary thyroid carcinoma
• A family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2

Patients with relevant history may require evaluation related to thyroid cancer or multiple endocrine neoplasia.

Semaglutide and Pregnancy

Semaglutide should not be used for weight reduction during pregnancy.

Current prescribing information instructs patients using Wegovy for weight reduction or cardiovascular-risk reduction to discontinue treatment when pregnancy is recognized.

Because semaglutide remains in the body for an extended period, current FDA labeling recommends discontinuing treatment at least two months before a planned pregnancy for weight-management or cardiovascular indications.

Patients who are planning pregnancy should discuss medication changes before conception.

Why Compounded Semaglutide Can Create Additional Dosing Risk

FDA-approved injectable Wegovy is supplied in standardized, labeled delivery systems.

Compounded semaglutide may instead be supplied in:

• Multidose vials
• Prefilled syringes
• Different concentrations
• Different syringe sizes

FDA has received reports of dosing errors involving compounded injectable semaglutide, including overdoses requiring hospitalization.

Confusion has occurred when patients or healthcare professionals have mixed up:

• Milligrams
• Milliliters
• Syringe units
• Different product concentrations

A patient prescribed compounded semaglutide should receive clear written instructions identifying the exact prescribed amount and how that amount relates to the supplied concentration and device.

Patients should not independently calculate or change their dose.

Adverse-Event Reports Involving Compounded Semaglutide

FDA continues to receive adverse-event reports associated with compounded semaglutide.

As of May 31, 2026, FDA reported receiving 990 adverse-event reports associated with compounded semaglutide.

An adverse-event report does not prove that the compounded product caused the event.

FDA also notes that adverse events may be underreported because many state-licensed pharmacies are not required to submit adverse-event reports to FDA in the same manner as manufacturers.

This reinforces the importance of physician follow-up and appropriate pharmacy selection.

How Should Patients Choose a Compounding Pharmacy?

If a physician determines that a compounded medication is medically and legally appropriate, the prescription should be filled by an appropriately licensed pharmacy operating under applicable law.

Patients should confirm:

• The pharmacy's identity
• State licensure
• The exact medication and concentration
• The form of semaglutide used
• Storage requirements
• Beyond-use date
• Instructions for administration
• How to contact the pharmacy with questions

Patients can learn more about individualized medication preparation through compounding pharmacy services.

Warning Signs With Online Semaglutide Sellers

Patients should be cautious when an online seller:

• Does not require evaluation by a licensed prescriber
• Markets compounded semaglutide as FDA-approved
• Calls the product a generic Wegovy or generic Ozempic
• Guarantees the same clinical results as an FDA-approved product
• Will not identify the dispensing pharmacy
• Sells a product labeled only for research use
• Uses semaglutide sodium or semaglutide acetate without a lawful basis
• Provides unclear dosing instructions

A low advertised price should not replace appropriate medical and pharmacy verification.

Compounded Semaglutide Cost

The cost of compounded semaglutide varies according to the prescriber, pharmacy, concentration, amount dispensed and associated medical program.

FDA-approved semaglutide pricing and insurance coverage also vary.

Cost should be considered alongside:

• Whether the medication is legally appropriate
• Whether an FDA-approved product can meet the patient's medical needs
• Pharmacy quality
• Medical follow-up
• Laboratory monitoring when indicated
• Long-term maintenance planning

A cheaper compounded medication should not be represented as medically equivalent to an approved product.

Is Compounded Semaglutide Better Than Brand-Name Semaglutide?

There is no evidence establishing compounded semaglutide as superior to FDA-approved Wegovy.

FDA-approved semaglutide has standardized manufacturing and an extensive clinical-trial program.

Compounding may serve a specific individual medical need, but that is different from demonstrating better effectiveness.

Is Compounded Semaglutide as Effective as Wegovy?

This has not been established.

The major STEP and SELECT trials evaluated standardized semaglutide formulations developed through the FDA-approved drug program.

A compounded product may contain semaglutide, but that does not establish:

• Identical purity
• Identical concentration
• Identical stability
• Identical pharmacokinetics
• Identical clinical effectiveness

Clinics should not promise that compounded semaglutide produces the same weight-loss results as Wegovy.

Semaglutide vs. Tirzepatide

Semaglutide and tirzepatide are different medications.

Semaglutide activates the GLP-1 receptor.

Tirzepatide activates both:

• GLP-1 receptors
• GIP receptors

Both have FDA-approved weight-management products and substantial human evidence.

The appropriate choice depends on:

• Medical history
• Previous treatment response
• Side effects
• Contraindications
• Insurance coverage and access
• Individual treatment goals

Patients should not combine semaglutide and tirzepatide unless specifically directed within an appropriate medical context. Routine concomitant GLP-1 therapy is not recommended.

Semaglutide vs. Traditional Weight-Loss Medication

Semaglutide is one of several prescription options for obesity treatment.

Other medications may affect:

• Appetite
• Satiety
• Cravings
• Fat absorption
• Central nervous system pathways

Patients can also review weight-loss medication options with a physician.

No single medication is best for every patient.

Semaglutide and Medical Weight-Loss Programs

Medication works best as one part of a complete weight-management plan.

A physician-guided program may address:

• Nutrition
• Physical activity
• Sleep
• Stress
• Metabolic health
• Weight-related medical conditions
• Medication side effects
• Body composition
• Weight-maintenance planning

This approach treats overweight and obesity as chronic medical conditions rather than short-term cosmetic concerns.

What Happens at a Semaglutide Weight-Loss Consultation?

Your first visit may include:

• Review of your weight history
• Previous diet and medication attempts
• Current medications
• Medical conditions
• Family history
• Blood pressure
• Body composition
• Nutrition and activity habits
• Sleep and stress
• Laboratory testing when indicated
• Review of FDA-approved medication options
• Discussion of whether a patient-specific compounded preparation is medically and legally appropriate

A consultation does not guarantee that semaglutide or compounded semaglutide will be prescribed.

Laboratory Testing During Medical Weight Loss

Testing is individualized according to medical history.

Possible measurements include:

• Fasting glucose
• Hemoglobin A1c
• Kidney function
• Liver function
• Lipid profile
• Thyroid testing
• Additional blood testing when clinically appropriate

Patients with diabetes may require closer glucose monitoring when weight-loss medications are combined with insulin or insulin-secretagogue therapy.

How Is Progress Monitored?

Physician-guided monitoring may include:

• Body weight
• Waist circumference
• Body-fat percentage
• Lean mass
• Blood pressure
• Appetite and dietary intake
• Gastrointestinal symptoms
• Strength and physical activity
• Blood glucose and A1c when relevant
• Medication tolerance

Monitoring can identify a weight-loss plateau , excessive loss of lean tissue or side effects that require a change in the plan.

Frequently Asked Questions About Compounded Semaglutide for Weight Loss

What is compounded semaglutide?

Compounded semaglutide is a prescription preparation made by a qualifying pharmacy or physician for an individual patient when applicable compounding requirements are satisfied. It is not FDA-approved.

Is compounded semaglutide legal?

Compounding can be lawful in patient-specific circumstances when all applicable federal and state requirements are met. Since the national semaglutide shortage has ended, routine mass compounding of products that are essentially copies of commercially available semaglutide is restricted.

Is compounded semaglutide FDA-approved?

No. FDA does not approve compounded semaglutide products before they are dispensed.

Is compounded semaglutide a generic Wegovy?

No. FDA specifically states that compounded drugs are not FDA-approved generic drugs and should not be marketed as such.

Is compounded semaglutide the same as Wegovy?

No. Wegovy is an FDA-approved, standardized semaglutide product. A compounded preparation does not undergo the same FDA review and should not be described as the same product.

Is compounded semaglutide the same as Ozempic?

No. Ozempic is an FDA-approved branded semaglutide medication with its own indications and standardized formulation. “Compounded Ozempic” is not an accurate description.

Can pharmacies still compound semaglutide after the shortage?

Patient-specific compounding may still be possible when Section 503A and applicable state requirements are satisfied. Routine compounding of essentially copies of commercially available semaglutide is restricted now that the shortage has ended.

When did the semaglutide shortage end?

FDA determined on February 21, 2025 that the national shortage of semaglutide injection products was resolved.

Can a doctor prescribe compounded semaglutide because it costs less?

Lower cost alone does not automatically create the patient-specific clinically significant difference contemplated by federal compounding policy.

Does adding vitamin B12 make compounded semaglutide different from Wegovy?

Not automatically. FDA specifically notes that adding another active ingredient such as vitamin B12 may still result in a product considered essentially a copy depending on the route, strength and circumstances.

What is compounded semaglutide with B12?

It is a compounded preparation containing semaglutide and cyanocobalamin. The combination itself is not FDA-approved for weight management and does not automatically qualify for lawful compounding simply because B12 is included.

What is semaglutide sodium?

Semaglutide sodium is a salt form that is chemically different from the semaglutide active ingredient used in FDA-approved products. FDA states it is not aware of a lawful basis for using semaglutide sodium in compounding.

What is semaglutide acetate?

Semaglutide acetate is another salt form that differs from the active ingredient in FDA-approved semaglutide medications. FDA has raised the same concern about its use in compounding.

How much weight can you lose with semaglutide?

In STEP 1, participants receiving the studied FDA-approved semaglutide regimen lost an average of 14.9% of body weight over 68 weeks. Individual results vary, and this figure should not be represented as a guaranteed result from compounded semaglutide.

How long does semaglutide take to work?

Appetite changes may occur earlier, but clinically meaningful weight reduction develops over months. Semaglutide is gradually escalated in approved regimens to improve tolerability.

How long can semaglutide be used?

FDA-approved Wegovy is intended for chronic weight management in appropriate patients. Long-term studies show sustained weight reduction during continued treatment. Treatment duration should be individualized.

Do patients regain weight after stopping semaglutide?

Weight regain is common after discontinuation. In the STEP 1 extension, participants regained approximately two-thirds of their prior semaglutide-associated weight loss over the following year on average.

Does semaglutide reduce appetite?

Yes. Clinical studies show effects on hunger, satiety, cravings and control of eating that contribute to reduced calorie intake.

Does semaglutide burn fat?

Semaglutide primarily helps reduce energy intake through appetite and satiety pathways. Weight loss includes changes in body fat and may also include lean tissue, which is why nutrition and resistance training matter.

Can semaglutide help insulin resistance?

Weight reduction and GLP-1 activity can improve glucose regulation. Clinical STEP analyses reported favorable glycemic changes among many participants with prediabetes.

Can semaglutide prevent diabetes?

Semaglutide treatment was associated with less progression toward diabetes and greater rates of normoglycemia in studied populations, but individual prevention decisions require broader metabolic care.

Does semaglutide protect the heart?

FDA-approved Wegovy reduces the risk of major adverse cardiovascular events in adults with established cardiovascular disease and obesity or overweight. This approved benefit should not automatically be attributed to a compounded preparation.

What are the most common semaglutide side effects?

Nausea, diarrhea, vomiting, constipation and abdominal symptoms are among the most common effects. Headache, fatigue, dizziness, reflux symptoms and hair loss can also occur.

Can semaglutide cause pancreatitis?

Acute pancreatitis has been observed with GLP-1 receptor agonists. Severe persistent abdominal pain requires prompt evaluation.

Can semaglutide cause gallstones?

Gallbladder disease, including gallstones, has been reported. Rapid or substantial weight loss can also increase gallstone risk.

Can semaglutide cause gastroparesis?

Semaglutide delays gastric emptying and may cause significant gastrointestinal symptoms. FDA-approved Wegovy is not recommended in patients with severe gastroparesis.

Can I use semaglutide if I have thyroid disease?

Common thyroid disorders are not the same as medullary thyroid carcinoma. However, Wegovy is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2.

Can semaglutide be used during pregnancy?

No weight-loss medication should be used to intentionally lose weight during pregnancy. Current Wegovy labeling instructs patients using it for weight reduction to discontinue when pregnancy is recognized and to stop at least two months before a planned pregnancy.

Why are dosing errors more common with some compounded semaglutide products?

Some compounded products are dispensed in multidose vials with varying concentrations. Confusion among milligrams, milliliters and syringe units can result in serious dosing errors.

Can I change my compounded semaglutide dose myself?

No. Dose changes should be directed by the prescribing clinician. Patients should not convert concentrations or syringe units independently.

Can I buy compounded semaglutide without a prescription?

Semaglutide is a prescription medication. Patients should avoid sellers that provide semaglutide without evaluation and a prescription from an appropriately licensed clinician.

Can I use research-grade semaglutide?

No. Products labeled for research use are not intended as medications for human treatment and should not be self-injected.

Is compounded oral semaglutide the same as Wegovy tablets?

No. FDA-approved Wegovy tablets use a standardized formulation supported by clinical and pharmacokinetic data. A compounded oral preparation should not be assumed to have equivalent absorption or effectiveness.

Is compounded semaglutide cheaper than Wegovy?

Prices vary. A lower price does not make a compounded drug equivalent to an FDA-approved product or establish that the compounded prescription meets current legal requirements.

What should I ask before accepting compounded semaglutide?

Ask why a compounded product is medically necessary for you, which form of semaglutide is used, which licensed pharmacy will prepare it, the exact concentration, how the dose is measured, storage instructions and how you will be monitored.

Should I choose compounded semaglutide or FDA-approved Wegovy?

FDA recommends that compounded drugs be used only when a patient's medical needs cannot be met by an FDA-approved drug. The decision should be made with a licensed clinician after reviewing approved options and any documented patient-specific need.

Explore Medical Weight-Loss Options in Noblesville, IN

Semaglutide has transformed obesity treatment, but FDA-approved semaglutide and compounded semaglutide are not interchangeable regulatory categories.

FDA-approved Wegovy has extensive clinical evidence for weight reduction and long-term weight management. Compounded semaglutide may be appropriate only in individualized circumstances that satisfy current compounding requirements.

A physician-guided evaluation can help determine whether semaglutide, another prescription medication, nutrition support, exercise planning or a broader metabolic program is appropriate for your goals.

Call (765) 259-0545 or contact Charles Turner MD online to request your consultation.

Medical References

• Once-Weekly Semaglutide in Adults With Overweight or Obesity: STEP 1 Randomized Trial
• Continued Semaglutide Supports Weight-Loss Maintenance: STEP 4 Randomized Withdrawal Trial
• Two-Year Effects of Semaglutide in Adults With Overweight or Obesity: STEP 5 Trial
• Semaglutide Improves Control of Eating Over Two Years in Adults With Overweight or Obesity
• Semaglutide Improves Glycemic Status in Adults With Prediabetes and Overweight or Obesity
• Semaglutide Reduces Major Cardiovascular Events in Adults With Cardiovascular Disease and Overweight or Obesity Without Diabetes
• Long-Term Weight-Loss Effects of Semaglutide in the SELECT Trial
• Semaglutide Reduces Body Weight and Knee Osteoarthritis Pain in Adults With Obesity